<DOC>
	<DOCNO>NCT00002876</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient recurrent ependymomas follow radiation therapy .</brief_summary>
	<brief_title>Etoposide Plus Cisplatin Treating Patients With Recurrent Ependymomas</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy toxicity etoposide cisplatin patient recurrent ependymomas . OUTLINE : All patient receive cisplatin follow etoposide day 1-3 . Treatment repeat every 4 week total 6 course unless disease progression unacceptable toxicity intervenes . The etoposide dose may increase 10 % subsequent course white blood cell platelet nadirs previous course least 3,000 100,000 , respectively . Patients follow every 2 month 6 month , every 3 month 4.5 year . PROJECTED ACCRUAL : A total 35 patient enter approximately 7 year 3-8 response first 13 patient 7-9 response first 25 patient .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ependymoma recurrent radiotherapy Histologic confirmation recurrence encourage require patient pure ependymoma diagnosis unequivocal radiologic evidence recurrence Histologic confirmation recurrence require patient mixed histology diagnosis Ependymoma least 80 % histology No subependymoma Measurable evaluable disease image exam PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Hematopoietic : WBC least 3,500 Platelets least 130,000 Hepatic : Bilirubin great 0.3 mg/dL normal Renal : Creatinine great 0.3 mg/dL normal Cardiovascular : No NYHA class III/IV status Other : No uncontrolled infection No pregnant nursing woman Negative pregnancy test require fertile woman Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cisplatin etoposide At least 4 week since chemotherapy ( 6 week since nitrosoureas ) Endocrine therapy : Steroid dose stable least 1 week prior entry indicator lesion CNS Radiotherapy : See Disease Characteristics At least 4 week since radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
</DOC>